Prof Xavier Leleu speaks to ecancer at the 2019 MyKE Myeloma meeting in Barcelona about various topics that surround the clinical implications that surround newly-diagnosed multiple myeloma.
He gives a summary of what was discussed in the first session he chaired. This included presentations about the prognostic features of high-, standard- and ultra-risk multiple myeloma, bone disease and neuropathy in multiple myeloma.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.